01.11.25 -- Cell & Gene Best Of December

With over 450 unique products in clinical development and 50 anticipated approvals by 2030, the evolving regulatory landscape for cell and gene therapies is more critical than ever. Don't miss your chance to gain expert insights! Join the next Cell & Gene Live for an exclusive digital panel discussion exploring forward-looking perspectives on this transformative field. Registration is free—thanks to the support of Thermo Fisher Scientific.

Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) discusses the biggest challenges in developing gene therapies.

It will be the first country to introduce a tailored framework for innovative medicine manufacturers at or close to where patients receive care.

The demand for plasmid DNA products is intrinsically linked to unique market conditions and funding environments. Here's what's driving them.

Uncover how a small-sized biotech company was able to resolve critical regulatory CMC deficiencies to meet FDA requirements.

Explore the evolving landscape of clinical trials focused on Alzheimer’s and Dementia, underscoring challenges and opportunities in developing precise treatments for diseases associated with aging.

Explore how by addressing challenges in differentiation, clone selection, and manufacturing, iPSC-based T cell therapies could revolutionize cancer treatment and other diseases.